Dosage and administration of landiolol

Landiolol is an ultra-short-acting, highly selective β1 receptor antagonist, mainly used for ventricular rate control in supraventricular tachycardia (such as atrial fibrillation, atrial flutter). Due to its rapid onset of action and short half-life, it is mainly administered via intravenous infusion in clinical practice and is suitable for acute patients who require rapid heart rate control. The specific dosage and administration method need to be individually adjusted according to the patient's cardiac function to ensure maximum efficacy and minimum adverse reactions.

1. Patients with normal heart function

For patients without significant impairment of cardiac function, the recommended starting dose is9 mcg/kg/minute, or 9 micrograms per kilogram of body weight per minute. Depending on the patient's clinical response and heart rate control, the dose may be increased every 10 minutes in increments of 9 mcg/kg/minute to a maximum dose of 36 mcg/kg/minute. Usually, landiolol can achieve the ideal heart rate control effect in a short time (about 10 minutes), so the patient's hemodynamic parameters, such as heart rate, blood pressure, etc., need to be closely monitored during the dose adjustment process to avoid the risk of hypotension or excessive bradycardia.

2. Patients with impaired cardiac function

For patients with cardiac dysfunction (such as those with chronic heart failure or reduced left ventricular ejection fraction), landiolol should be used with more caution. The initial dose in such patients is significantly reduced, usually 1 mcg/kg/minute. Subsequently, gradual titration can be carried out according to the clinical situation, with each increase of 1 mcg/kg/minute, and the adjustment interval is extended to 15 minutes. The maximum dose is still 36 mcg/kg/minute. Because patients with impaired cardiac function are more susceptible to decreased cardiac output due to beta-blockade, blood pressure, heart rate, and other cardiac function indicators, such as left ventricular ejection fraction (LVEF), must be closely monitored during dose adjustment.

3. Medication method

Landiolol requires continuous intravenous infusion and should not be administered as an intravenous bolus to prevent an excessively rapid decrease in heart rate or sudden drop in blood pressure. During the infusion, ECG monitoring should be continued and hemodynamic status should be assessed regularly to determine whether dosage adjustment or discontinuation is needed.

4. Precautions for discontinuing medication

Landiolol has a short half-life (approximately4 minutes), its drug effect disappears quickly, so the heart rate usually recovers faster after stopping the drug. However, for patients who have relied on beta-blockers for a long time, sudden discontinuation may trigger sympathetic nerve excitement, lead to a rebound increase in heart rate, and even induce angina or arrhythmia. Therefore, when discontinuing landiolol infusion, the dose should be gradually reduced rather than discontinued immediately to prevent adverse cardiac effects.

In summary, the dosage and administration method of landiolol need to be individually adjusted strictly according to the patient's cardiac function, and closely monitored during the medication period to ensure safe and effective heart rate control while reducing the risk of adverse reactions such as hypotension and bradycardia.

-Patients with normal cardiac function:

The starting dose is9mcg/kg/minute; according to clinical indications, the dose can be increased by 9mcg/kg/minute at 10-minute intervals to a maximum dose of 36mcg/kg/minute.

-Patients with impaired cardiac function:

The starting dose is1mcg/kg/minute; according to clinical indications, the dose can be increased by 1mcg/kg/minute at 15-minute intervals to a maximum dose of 36mcg/kg/minute.

Reference materials:https://www.drugs.com/rapiblyk.html